Compare, Analyse Natco Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the worlds leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industrys broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NATCO PHARMA   MYLAN
EQUITY SHARE DATA
    NATCO PHARMA
Mar-19
MYLAN
Dec-18
NATCO PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs8493,478-   
Low Rs5571,914-   
Sales per share (Unadj.) Rs573.81,600.4-  
Earnings per share (Unadj.) Rs176.043.5-  
Cash flow per share (Unadj.) Rs198.2343.1-  
Dividends per share (Unadj.) Rs6.250-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs842.71,731.4-  
Shares outstanding (eoy) m36.50514.50-   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x1.21.7 72.7%   
Avg P/E ratio x4.062.0 6.4%  
P/CF ratio (eoy) x3.57.9 45.1%  
Price / Book Value ratio x0.81.6 53.6%  
Dividend payout %3.60-   
Avg Mkt Cap Rs m25,6601,387,238 1.8%   
No. of employees `0005.035.0 14.2%   
Total wages/salary Rs m3,5590-   
Avg. sales/employee Rs Th4,225.323,526.5 18.0%   
Avg. wages/employee Rs Th718.00-   
Avg. net profit/employee Rs Th1,295.9638.8 202.9%   
INCOME DATA
Net Sales Rs m20,945823,426 2.5%  
Other income Rs m1,3020-   
Total revenues Rs m22,247823,426 2.7%   
Gross profit Rs m7,948213,072 3.7%  
Depreciation Rs m810154,178 0.5%   
Interest Rs m19339,604 0.5%   
Profit before tax Rs m8,24719,290 42.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,823-3,069 -59.4%   
Profit after tax Rs m6,42422,359 28.7%  
Gross profit margin %37.925.9 146.6%  
Effective tax rate %22.1-15.9 -138.9%   
Net profit margin %30.72.7 1,129.5%  
BALANCE SHEET DATA
Current assets Rs m23,472459,800 5.1%   
Current liabilities Rs m7,287335,245 2.2%   
Net working cap to sales %77.315.1 510.9%  
Current ratio x3.21.4 234.9%  
Inventory Days Days9284 110.3%  
Debtors Days Days8893 94.5%  
Net fixed assets Rs m18,648159,731 11.7%   
Share capital Rs m365438 83.3%   
"Free" reserves Rs m34,5250-   
Net worth Rs m30,760890,796 3.5%   
Long term debt Rs m0961,455 0.0%   
Total assets Rs m43,0312,389,462 1.8%  
Interest coverage x43.71.5 2,940.7%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.50.3 141.2%   
Return on assets %15.42.6 593.0%  
Return on equity %20.92.5 832.0%  
Return on capital %27.43.2 862.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m8,5970-   
CASH FLOW
From Operations Rs m6,688171,108 3.9%  
From Investments Rs m-6,122-88,444 6.9%  
From Financial Activity Rs m-509-79,712 0.6%  
Net Cashflow Rs m661,418 4.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 73.07 Rs / USD

Compare NATCO PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare NATCO PHARMA With: STRIDES PHARMA SCIENCE  ABBOTT INDIA  FDC  NOVARTIS  SUVEN LIFE SCIENCES  



Today's Market

Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)

The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.

Related Views On News

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living (Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Access Now: Eight Steps to Your Eight Figure Fortune
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

NATCO PHARMA SHARE PRICE


Feb 26, 2021 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NATCO PHARMA

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

FEATURED VIDEOS

Nifty is Weak but Smallcaps Can Outperform

Gold 65,000 and Silver 84,000 in 2022

How Long Before a Big Stock Market Crash

I Believe the Investment of the Year Will Be...

More Featured Videos

MARKET STATS